The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.v

Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

The DLCO/KCO are impacted more often than volumes and flows. Changes concomitant with the administration of chemotherapy, and tend to resolve after completion of treatment. Residual defect may persist longterm

Publications

Keikhaei B, Bahadoram M, Keikha A, Bahadoram S, Hassanzadeh S, Mahmoudian-Sani MR

Late side effects of cancer treatment in childhood cancer survivors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2023;29(4):885-892

Keldsen N, Jöhnk ML, Ejlersen JA

Impairment of Lung Function During Adjuvant Oxaliplatin Treatment in Patients with Colorectal Cancer: A Prospective Trial.

Current drug safety. 2016;11(3):215-21

Patel A, Weismann C, Weiss P, Russell K, Bazzy-Asaad A, Kadan-Lottick NS

Association between right ventricular dysfunction and restrictive lung disease in childhood cancer survivors as measured by quantitative echocardiography.

Pediatric blood & cancer. 2014;61(11):2059-64

Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ

Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.

Chest. 2009;135(6):1588-1595

Myers JN, O'neil KM, Walsh TE, Hoffmeister KJ, Venzon DJ, Johnson BE

The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation.

Chest. 2005;128(5):3261-8

Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, Sklar C, Robison LL, Childhood Cancer Survivor Study

Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study.

Cancer. 2002;95(11):2431-41

Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, Dimopoulos MA

A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.

Cancer. 2002;94(2):452-8

Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, Hudson MM, Stokes DC, Bozeman PM

Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarba

Cancer. 1995;75(7):1706-11